Drug Information

Drug General Information
Drug ID
D0TC4R
Former ID
DNCL001900
Drug Name
Desmoteplase
Indication Ischemic stroke [ICD9: 434.91; ICD10:I61-I63] Phase 3 [521641]
Company
Lundbeck Research
Target and Pathway
Target(s) Plasminogen Target Info Activator [526538]
KEGG Pathway Neuroactive ligand-receptor interaction
Complement and coagulation cascades
Staphylococcus aureus infection
Influenza A
PANTHER Pathway Blood coagulation
Plasminogen activating cascade
Pathway Interaction Database Angiopoietin receptor Tie2-mediated signaling
p75(NTR)-mediated signaling
amb2 Integrin signaling
Syndecan-4-mediated signaling events
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
PathWhiz Pathway Coagulation
Reactome Platelet degranulation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Dissolution of Fibrin Clot
WikiPathways Complement and Coagulation Cascades
Human Complement System
Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Activation of Matrix Metalloproteinases
Blood Clotting Cascade
Dissolution of Fibrin Clot
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 521641ClinicalTrials.gov (NCT00111852) Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2). U.S. National Institutes of Health.
Ref 526538Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.